Patents Represented by Attorney, Agent or Law Firm Giulio A. DeConti
-
Patent number: 6524807Abstract: Modified forms of human interleukin-1&bgr; converting enzyme (ICE) that display proteolytic activity and, furthermore, have increased stability compared to unmodified human ICE are disclosed. Nucleic acid molecules encoding a modified p10 subunit of ICE, and recombinant vectors and host cells incorporating such nucleic acid molecules, are also disclosed. A modified ICE protein of the invention can be used to cleave proteolytically ICE substrates and to identify modulators of ICE activity in screening assays. Moreover, due to its enhanced stability, the modified ICE of the invention is particularly suitable for use in the preparation of ICE crystals for X-ray crystallography.Type: GrantFiled: April 6, 2001Date of Patent: February 25, 2003Assignee: BASF AktiengellschaftInventors: Robert V. Talanian, John A. Mankovich, Tariq Ghayur, Catherine R. Ferenz
-
Patent number: 6512117Abstract: A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.Type: GrantFiled: November 9, 2000Date of Patent: January 28, 2003Assignee: Abbott LaboratoriesInventors: William H. Harclerode, Robert Gault, Mark D. Sandison
-
Patent number: 6509015Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., Kd=10−8 M or less), a slow off rate for hTNF&agr; dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 31, 2000Date of Patent: January 21, 2003Assignee: BASF AktiengesellschaftInventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 6506751Abstract: Disclosed are compounds of the Formula I wherein: Z is C or nothing, provided that when Z is nothing, R3 and R4 are nothing; A is S, S═O or O═S═O; R1 and R2 are independently hydrogen, lower alkyl, halogen, hydroxy or lower alkoxy, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heteroaryl or(un)substituted heteroarylakyl; R3 and R4 independently represent hydrogen, lower alkyl, cycloalkyl, aminoalkyl, mono- or dialkylaminoalkyl, (un)substituted aryl or (un)substituted heteroaryl; R5 represents a (un)substituted carbocyclic group containing from 3-7 members, up to two of which members are optionally hetero atoms; or R5 is (CR6R7)—(CH2)n—XR8R9; X is S or N; R6, R7, R8, R9, and n are as defined in the specification. The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the preparation of the final products, pharmaceutical compositions containing the final products are also taught.Type: GrantFiled: November 2, 2000Date of Patent: January 14, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Stephanie Elizabeth Ault Justus, Helen Tsenwhei Lee, Jason Keith Pontrello, Bruce David Roth, Karen Elaine Sexton, Michael William Wilson
-
Patent number: 6504008Abstract: The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell.Type: GrantFiled: February 1, 1999Date of Patent: January 7, 2003Assignee: Cadus Technologies, Inc.Inventors: Jun Xu, Joshua Trueheart
-
Patent number: 6491912Abstract: Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine cardiomyocytes can be modified such that an antigen (e.g., an MHC class I antigen) on the cardiomyocyte surface which is capable of stimulating an immune response against the cardiomyocytes in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cardiomyocyte when introduced into the subject. In one embodiment, the porcine cardiomyocytes are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject.Type: GrantFiled: March 16, 1999Date of Patent: December 10, 2002Assignee: Diacrin, Inc.Inventor: Jonathan Dinsmore
-
Patent number: 6482586Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.Type: GrantFiled: November 21, 1997Date of Patent: November 19, 2002Assignee: Hospital for Sick Children Research and Development Limited PartnershipInventors: Sara Arab, Clifford A. Lingwood, Aye-Aye Khine
-
Patent number: 6479296Abstract: A new method, solid phase precipitation and extraction (SPPE), is disclosed and is particularly advantageous for purifying mixtures of synthetic peptides directly from a cleavage/deprotection mixture.Type: GrantFiled: July 6, 2000Date of Patent: November 12, 2002Inventors: Alex G. Bonner, Lawrence S. Udell, William A. Creasey, Stephen Duly, Richard A. Laursen
-
Patent number: 6479712Abstract: Methods for producing perfluorocarbon monomethanols or dimethanols are disclosed. The methods of the invention can provide branched perfluorocarbon monomethanols or dimethanols with good purity and yields.Type: GrantFiled: July 13, 1999Date of Patent: November 12, 2002Assignee: Exfluor Research CorporationInventor: Hajimu Kawa
-
Patent number: 6479074Abstract: The present invention features methods and compositions for transdermal administration. In one embodiment, the invention features methods and compositions for transdermal administration of an amine containing compound having biphasic solubility and/or an agent which enhances the activity of the amine containing compound having biphasic solubility, e.g., a muscle relaxant, to relieve pain.Type: GrantFiled: April 2, 2001Date of Patent: November 12, 2002Assignee: Pharmaceutical Applications Associates LLCInventors: Robert W. Murdock, C. Donald Williams
-
Patent number: 6475806Abstract: An anchor library is described. A collection of recombinant vectors having a nucleic acid encoding a displayed peptide sequence is provided. The displayed peptide sequence of each of the vectors comprises X1(Y1)c1X2(Y2)c2X3(Y3)c3X4, wherein each X1, X2, X3 and X4 is an amino acid residue and any of X1, X2, X3 and X4 can be the same or different from any one other, wherein each Y1, Y2 and Y3 is alanine or glycine or a combination of alanine and glycine that is respectively c1, c2 and c3 amino acid residues long and any of Y1, Y2 and Y3 if present can be the same or different from any one other, wherein each of c1, c2 and c3 is 0 to about 20, wherein X1 and X4 are each attached to an amino acid residue that flanks the displayed peptide sequence. Preferably, at least about 105 to about 108 permutations of all possible permutations of the displayed peptide sequence are present in the anchor library.Type: GrantFiled: June 7, 1995Date of Patent: November 5, 2002Assignee: Praecis Pharmaceuticals, Inc.Inventors: Howard Benjamin, Ethan Signer, Malcolm Gefter
-
Patent number: 6469048Abstract: Novel &agr;-pyrones are described. The &agr;-pyrones are useful in a method for controlling &agr;-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an &agr;-pyrone such that control of &agr;-pyrone responsive states in a mammal occurs. &agr;-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel &agr;-pyrones are also described.Type: GrantFiled: July 30, 1999Date of Patent: October 22, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Seth Cohen, Zhi-Dong Jiang
-
Patent number: 6458842Abstract: There is disclosed a liquid pharmaceutical composition comprising a therapeutic agent which comprises: one or more thyroid hormone or hormones; from about 40% to about 96% ethanol by volume; a pH adjusting agent so that the measured pH of the composition is from about 9 to about 12; and from about 4% to about 50% water by volume; which has utility in the treatment of disorders associated with an impairment of the thyroid hormone function in animals including human beings. The liquid composition may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray.Type: GrantFiled: July 31, 1996Date of Patent: October 1, 2002Assignee: Knoll AktiengesellschaftInventors: Jeffrey Dickinson, Karrar Ahmad Khan, John Neville Hague, Alan Smith
-
Patent number: 6458765Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L (I), and acid salts thereof, wherein A, B, D, E, F, G and K are &agr;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: July 18, 2000Date of Patent: October 1, 2002Assignee: BASF AktiengesellschaftInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Patent number: 6445941Abstract: A novel method and apparatus for obtaining the electrocardiogram (ECG) in small conscious animals, such as mice, without the need to anesthetize or instrument the animal, are described. The apparatus includes an array of conductive pads, embedded in a platform, the pads sized and spaced to advance contact between an animal's paws and the pads as the animal freely moves upon the platform. Electrical circuitry to the pads is configured to sense the parings of pads and paws that render an interpretable ECG signal and to activate or deactivate recording of the signals. The apparatus is suspended above a surface to minimize the range of motion of the animal without physical restraint.Type: GrantFiled: March 11, 2000Date of Patent: September 3, 2002Inventors: Thomas G. Hampton, Jose M. Otero
-
Patent number: 6444205Abstract: Methods for using neural cells to treat chronic pain and/or spasticity are described. The neural cells can be derived from any mammal, and are preferably human or porcine in origin. The neural cells preferably are serotonergic cells or are gamma-aminobutryic acid (GABA)—producing cells. Neural cells can be obtained from adult, juvenile, embryonic or fetal donors. Neural cells can be modified to be suitable for transplantation into a subject. For example, the neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject or can be genetically modified to produce a factor.Type: GrantFiled: September 30, 1998Date of Patent: September 3, 2002Assignee: Diacrin, Inc.Inventors: Jonathan Dinsmore, Julie Siegan
-
Patent number: 6432675Abstract: The invention provides a method of generating a set of polypeptide antigens derived from a protein (or portion thereof) which is expressed with some degree of sequence heterogeneity among naturally or artificially induced variants of the protein. The purpose is to provide a mix of antigens which can be used to immunize against the variants and, preferably, possible unknown or new variants that may arise.Type: GrantFiled: July 24, 1995Date of Patent: August 13, 2002Inventor: Roberto Crea
-
Patent number: 6423686Abstract: Methods of treating a subject having a disorder associated with LHRH activity are disclosed.Type: GrantFiled: April 6, 1998Date of Patent: July 23, 2002Assignee: Advanced Research & Technology InstituteInventor: Roger W. Roeske
-
Patent number: 6416948Abstract: The invention provides methods for the identification of members of a malignant lymphocyte clone by analysis of clonotypic DNA rearrangements of T cell or B cell receptor genes. The DNA or RNA from isolated single tumor cells is amplified by PCR using consensus primers to the VDJ region of the receptor genes, and the sequence of the VDJ region is obtained from each. The clonotypic sequence of the malignant clone is identified as the most frequent VDJ sequence amplified. Individual-specific PCR primers for the VDJ region are then designed based upon the clonotypic sequence. These specific PCR primers are used to detect and quantitate clonotypic cells in subsequent patient samples using in situ PCR or in situ RT-PCR. Fractionated or unfractionated samples of blood or bone marrow, as well as tissue sections can be analyzed.Type: GrantFiled: April 1, 1999Date of Patent: July 9, 2002Assignee: The Governors of the University of AlbertaInventors: Linda M. Pilarski, Andrew R. Belch, Agnieszka J. Szczepek
-
Patent number: 6410261Abstract: Isolated nucleic acid molecules encoding a novel protein, CIP104, that interacts with CIITA, an MHC class II transcriptional activator, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a CIP104 transgene. The invention further provides isolated CIP104 proteins and peptides, CIP104 fusion proteins and anti-CIP104 antibodies. Methods of using the CIP104 compositions of the invention are also disclosed, including methods for detecting CIP104 activity (e.g., CIP104 protein or mRNA) in a biological sample, methods of modulating CIP104 activity in a cell, and methods for identifying agents that modulate an interaction between CIP104 and CIITA.Type: GrantFiled: November 6, 1997Date of Patent: June 25, 2002Assignee: President and Fellows of Harvard CollegeInventors: Laurie H. Glimcher, Hong Zhou